Jubilant Life Sciences receives ANDA approvals for Irbesartan and Cetirizine

On 24 February 2015

Jubilant Life Sciences announced that the company has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Irbesartan Tablets USP, 75 mg, 150 mg, and 300 mg. and Cetirizine Hydrochloride Tablets (Chewable), 5 mg and 10 mg. The total market size for Irbesartan Tablets as per IMS is approximately $50 million per annum.

Powered by Capital Market - Live News